Evidence map›Paper›PMID 33211091›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

A High Percentage of People With Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following Coronavirus Disease 2019 (COVID-19).

Michael J Peluso, Sonia Bakkour, Michael P Busch, Steven G Deeks, Timothy J Henrich

Abstract readLetterComment
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Michael J PelusoDivision of Infectious Diseases, University of California, San Francisco, San Francisco, California, USA.
Sonia BakkourVitalant Research Institute, San Francisco, California, USA.ORCID 0000-0001-8773-0740
Michael P BuschVitalant Research Institute, San Francisco, California, USA.
Steven G DeeksDivision of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, San Francisco, California, USA.
Timothy J HenrichDivision of Experimental Medicine, University of California, San Francisco, San Francisco, California, USA.

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Targeting Non Viral Markers of HIV PersistenceR01AI141003 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2018 to 2022
$4.9M
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinicR01AI158013 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, SPINELLI, MATTHEW A. · 2020 to 2023
$3.1M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
NIAID NIH HHS K23 AI157875NIAID NIH HHS L30 AI147159NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI141003NIAID NIH HHS R01 AI158013NIAID NIH HHS T32 AI060530NIH HHS 3R01AI-141003-03S1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-HIV AgentsCOVID-19HIV-1HIV InfectionsHumansRNASARS-CoV-2Anti-HIV AgentsRNA

Identifiers

PMID33211091
PMCPMC7717237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.